Investment Considerations

• Significant Portfolio of 346 identified biomarkers and patents, 19 pending and 1 issued patent.
• Proprietary protein techniques that yield high quality, highly sensitive, reproducible results
• Over 50 years of combined proteomics experience
• Technologies/products in large and growing markets
• Strategically positioned to commercialize technology and become the "dominant player" in the protein-based diagnostic market
• Significant revenue opportunities from licensing of discovered biomarkers to large diagnostic companies
• Dedicated management and world class scientific advisory board

Strategy
Capitalize on protein pattern and biomarker discoveries and commercially validate science. Focus development effort on protein-based early diagnostic test and drug target market

Partnerships & Alliances

• Licensing agreement with Biosite(NASDAQNM:BSTE) to develop protein biomarker antibodies for diagnostic tests.
• Research agreement with New Horizons Diagnostics Corporation to develop diagnostic test for neurodegenerative disease
• Exclusive licensing agreement with Baylor College of Medicine to produce, market & sell technology related to biomarkers of neurodegenerative disease
• Future licensing agreements planned with diagnostic & pharmaceutical companies